The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Study critique · continued

Immortal time bias in a claims-database study posts 31–35

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

MD
m.dalgaardTL3Regular26 Aug 2025#31

Small methodological point on immortal time bias: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.

0 likes 11mo
FR
f.rasmussenTL228 Aug 2025 · edited#32

Reporting bias within a paper — a result in a figure that is absent from the abstract — is checkable and is worth checking when the claim matters.

I would want the raw data before agreeing with my own summary of it.

3 likes 11mo
PR
policy_readerTL2Regular29 Aug 2025#33

Post #31 is the version of this I will quote in future. One addition.

Multiple comparisons: if a paper reports many outcomes, the chance of a spurious association by random chance is real. Pre-specification of primary outcomes matters and secondary analyses are weaker evidence.

15 likes 11mo
EA
e.adeyemiTL230 Aug 2025#34
m.dalgaard, post #31: Small methodological point on immortal time bias: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone. Go to post

Where I part company with post #32, and it is a narrow parting.

Having read the whole immortal time bias thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.

30 likes in reply to #31 11mo
GT
g.tanakaTL3Regular31 Aug 2025#35

Publication bias: a single published positive trial is weaker evidence than multiple published trials with consistent results. Asking whether there are unpublished negative trials is a fair critical question.

One case, stated as one case.

0 likes 11mo
This topic was closed 45 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

TopicParticipantsRepliesViewsActivity
Critiquing an observational claim about a class effect
Posting this under the heading it deserves: Critiquing an observational claim about a class effect Everything below is what sits behind that. I was wrong about critiquing an observational claim in a thread…
VRRIJV 2 6.9k 14mo
A well-designed study with a badly written abstract
Posting this under the heading it deserves: A well-designed study with a badly written abstract Everything below is what sits behind that. Reading back through what has been written here about well-designed…
RCMICBMRPN+117 128 7.2k 14mo
Confounding by indication, explained with a concrete example
On the subject in the title: Confounding by indication, explained with a concrete example Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-2 ( N Engl J Med ,…
TVARBDSBCD+21 25 21k 11mo
A claim built entirely on a subgroup analysis
A claim built entirely on a subgroup analysis Writing it up because I had to work it out twice and would rather nobody else did. I would like to disagree carefully with the settled view on claim built, and I…
ASKHMIASNP+71 80 1.1k 14mo
A structured critique template this community uses — a second dataset
On the subject in the title: A structured critique template this community uses — a second dataset Working notes rather than a conclusion. Posting a small dataset on structured critique template. It is mine,…
PRFLKBACAW+47 51 16k 15h

Related topics — sharing the tags risk of bias, observational data, disputed

TopicParticipantsRepliesViewsActivity
Journal club: STEP-HFpEF and symptom endpoints — a second dataset
On the subject in the title: Journal club: STEP-HFpEF and symptom endpoints — a second dataset Working notes rather than a conclusion. Posting a small dataset on step-hfpef and symptom endpoints. It is mine,…
EDCRFKTVIA+11 15 4k 10mo
Journal club: STEP 8 and the fairness of the comparator dose — a second dataset
Posting this under the heading it deserves: Journal club: STEP 8 and the fairness of the comparator dose — a second dataset Everything below is what sits behind that. Posting a small dataset on STEP 8. It is…
OLIADSRFDO+18 22 656 13h
Follow-up: A supplier that answers analytical questions with restated claims
A supplier that answers analytical questions with restated claims — setting out what I have, and where I think it stops being reliable. A follow-up question about supplier that I did not know to ask the first…
CCPYESTCB+74 82 2.8k 6mo
Journal club: semaglutide in MASH, and surrogate endpoints
Posting this under the heading it deserves: Journal club: semaglutide in MASH, and surrogate endpoints Everything below is what sits behind that. Working notes on semaglutide in MASH rather than a conclusion.…
MDSRSGSLSC+24 28 17k 15h
When a preprint is the best available evidence and we say so
When a preprint is the best available evidence and we say so — that is the question, and I have not found it answered plainly anywhere I have looked. A preprint question rather than a question about the…
CPNMKMJE+148 160 31k 11mo